Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
Arch Immunol Ther Exp (Warsz)
; 58(3): 165-78, 2010 Jun.
Article
em En
| MEDLINE
| ID: mdl-20373147
ABSTRACT
Harnessing the power of the immune system to target cancer has long been a goal of tumor immunologists. One avenue under investigation is the modification of T cells to express a chimeric antigen receptor (CAR). Expression of such a receptor enables T-cell specificity to be redirected against a chosen tumor antigen. Substantial research in this field has been carried out, incorporating a wide variety of malignancies and tumor-associated antigens. Ongoing investigations will ensure this area continues to expand at a rapid pace. This review will explain the evolution of CAR technology over the last two decades in addition to detailing the associated benefits and disadvantages. The outcome of recent phase I clinical trials and the impact that these have had upon the direction of future research in this field will also be addressed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Imunoterapia Adotiva
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article